A Bayesian approach to an integrated multimodal noninvasive diagnosis of definitive nonalcoholic steatohepatitis in the spectrum of nonalcoholic fatty liver disease

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 11, 2014, Pages 1292-1295

  Yilmaz, Yusuf ^a,b   Eren, Fatih ^b  

^a Section of Pediatric Epileptology and Video EEG Lab Acibadem   (Turkey)

^b MARMARA UNIVERSITY   (Turkey)

Author keywords

Bayes' theorem; Fibroscan; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Noninvasive diagnosis

Indexed keywords

CYTOKERATIN 18; BIOLOGICAL MARKER;

ADULT; ARTICLE; BAYES THEOREM; BLOOD SAMPLING; DIABETES MELLITUS; ELASTOGRAPHY; FEMALE; HUMAN; HYDROGEN BREATH TEST; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE ACTIVITY SCORE; PATHOLOGIST; PREDICTION; PRIORITY JOURNAL; TERTIARY CARE CENTER; BIOPSY; BLOOD; BREATH ANALYSIS; DECISION SUPPORT SYSTEM; DIFFERENTIAL DIAGNOSIS; EVALUATION STUDY; LIVER; MIDDLE AGED; MULTIMODAL IMAGING; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PROCEDURES;

ADULT; BAYES THEOREM; BIOLOGICAL MARKERS; BIOPSY; BREATH TESTS; DECISION SUPPORT TECHNIQUES; DIAGNOSIS, DIFFERENTIAL; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; KERATIN-18; LIVER; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84927624262     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000184     Document Type: Article

References (32)

1. Bhala N, Jouness RI, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des 2013; 19:5169-5176.
2. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34:274-285.
3. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8 (SUPPL. 1):S4-S8.
4. Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol (N Y) 2012; 8:661-668.
5. Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res 2013; 1:7.
6. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20:475-485.
7. Yilmaz Y. Biomarkers for early detection of non-alcoholic steatohepatitis: implications for drug development and clinical trials. Curr Drug Targets 2013; 14:1357-1366.
8. Yilmaz Y, Eren F. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clin Chim Acta 2012; 414:154-157.
9. Younossi ZM, Page S, Rafiq N., Birerdinc A, Stepanova M, Hossain N., et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011; 21:431-439.
10. Younossi ZM, Jarrar M, Nugent C., Randhawa M, Afendy M, Stepanova M., et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; 18:1430-1437.
11. Lau EW, Pathamanathan RK, Ng G.A., Cooper J., Skehan JD, Griffith MJ. The Bayesian approach improves the electrocardiographic diagnosis of broad complex tachycardia. Pacing Clin Electrophysiol 2000; 23 (Pt 1):1519-1526.
12. Fletcher J, Fox R. Pattern recognition versus Bayesian approach for diagnosis in primary care. BMJ 2006; 332:646.
13. Zhou H, Lawson AB, Hebert J.R., Slate EH, Hill EG. A Bayesian hierarchical modeling approach for studying the factors affecting the stage at diagnosis of prostate cancer. Stat Med 2008; 27:1468-1489.
14. De Icaza E, López-Cervantes M, Arredondo A, Robles-Díaz G. Likelihood ratios of clinical, laboratory and image data of pancreatic cancer: Bayesian approach. J Eval Clin Pract 2009; 15:62-68.
15. Chen J, Zhu Y, Zheng Q., Jiang J. Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: a meta-analysis. Hepatol Res 2013 [Epub ahead of print].
16. Yilmaz Y, Dolar E, Ulukaya E., Akgoz S, Keskin M, Kiyici M., et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 2007; 13:837-844.
17. Portincasa P, Grattagliano I, Lauterburg B.H., Palmieri VO, Palasciano G, Stellaard F. Liver breath tests non-invasively predict higher stages of nonalcoholic steatohepatitis. Clin Sci (Lond) 2006; 111:135-143.
18. Park GJ, Wiseman E, George J., Katelaris PH, Seow F, Fung C, Ngu MC. Non-invasive estimation of liver fibrosis in non-alcoholic fatty liver disease using the 13 C-caffeine breath test. J Gastroenterol Hepatol 2011; 26:1411-1416.
19. Sandrin L, Fourquet B, Hasquenoph J.M., Yon S., Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29:1705-1713.
20. Wong GL. Update of liver fibrosis and steatosis with transient elastography (Fibroscan). Gastroenterol Rep (Oxf) 2013; 1:19-26.
21. De Lédinghen V, Wong VW, Vergniol J, Wong GL, Foucher J, Chu SH, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. J Hepatol 2012; 56:833-839.
22. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos M.J., Cummings OW, et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41:1313-1321.
23. Musso G, Gambino R, Pacini G., De Michieli F, Cassader M. Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. Am J Clin Nutr 2009; 89:558-567.
24. Eisenmann A, Amann A, Said M., Datta B, Ledochowski M. Implementation and interpretation of hydrogen breath tests. J Breath Res 2008; 2:046002.
25. Yilmaz Y, Yesil A, Gerin F., Ergelen R, Akin H, Celikel ÇA, Imeryuz N. Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scand J Gastroenterol 2014; 49:611-616.
26. Petta S, Vanni E, Bugianesi E., Di Marco V, Cammà C, Cabibi D, et al. The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2014 [Epub ahead of print].
27. Arun J, Clements RH, Lazenby A.J., Leeth RR, Abrams GA. The prevalence of nonalcoholic steatohepatitis is greater in morbidly obese men compared to women. Obes Surg 2006; 16:1351-1358.
28. Marchesini G, Bugianesi E, Forlani G., Cerrelli F, Lenzi M, Manini R., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917-923.
29. Kim CH, Younossi ZM. Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleve Clin J Med 2008; 75:721-728.
30. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009; 13:9-19.
31. Sanyal AJ, Brunt EM, Kleiner D.E., Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology 2011; 54:344-353.
32. Krawczyk M, Portincasa P, Lammert F. PNPLA3-associated steatohepatitis: toward a gene-based classification of fatty liver disease. Semin Liver Dis 2013; 33:369-379.